News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fuse Science Set to Redefine OTC and Pharmaceutical Delivery with Roll-on Application Technology



11/7/2012 2:18:07 PM

MIAMI LAKES, Fla., Nov. 6, 2012 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) an innovative company that possesses proprietary delivery technology set to redefine how consumers receive energy, medicines, vitamins and minerals, today provides further insight into the numerous potential applications of its technology arising from Fuse Science's most recent scientific testing research results.

Fuse Science recently disclosed the results of its research findings which provide proof-of-concept for its proprietary transdermal delivery technology, demonstrating that it can effectively deliver various compounds such as insulin through the epidermis with a simple roll-on application. The Company detailed its perceived ability to completely reinvent the $3 billion dollar patch market by supplanting patches with roll-ons.

Today, Fuse Science further announces that its proprietary technology is also set to potentially redefine the use of oral delivery in several OTC and pharmaceutical categories. "When treating any medical or nutritional condition, the routes of administration chosen may have a profound impact upon the speed and efficiency with which the active takes effect," said David Berkoff, M.D., a practicing physician and member of Fuse Science's Board of Directors. "When medications are taken orally, there can be several disadvantages such as decreased efficacy as actives are destroyed in the stomach, delayed onset which may not be optimal for emergencies, unpleasant taste, and the inability to use oral delivery whether in the unconscious patient or other instances where an alternative delivery method is required."

"No single method of drug administration is ideal for all drugs in all circumstances," said Jeanne Hebert, Vice President Marketing and Clinical Research. "However, there is a distinct advantage of providing a transdermal application, especially with the younger and older populations. In both cases, compliance can be an issue, when taking oral medications due to multiple factors including: the size of the pill, the age of the patient, the frequency of the dosing and the side effects. Transdermal absorption has its benefits. There is no breakdown of medication in the GI tract, ease of application and the route of administration can begin within minutes."

In third world countries and active military conditions, swallowing a pill with clean drinking water is not always possible. The ability to deliver much needed medications and nutrition through the skin provides an excellent and needed alternative. Fuse Science's proprietary delivery technology has the potential to significantly improve numerous medical therapies and product efficacy in critical life conditions, such as diabetic care, cancer treatment, child nutrition and many others.

Fuse Science is continuing its work with New York-based investment banking firm Atlas Strategic Advisors (www.atlasadvisors.com) to explore strategic transactions involving Fuse Science's proprietary technology. Additionally, Fuse Science is being advised by Gaurav Kapoor, former Managing Partner and Principal at New England Consulting Group, where he worked for 15 years, leading landmark M&A and licensing transactions in the pharmaceutical and consumer package goods industries.

About Fuse Science, Inc.

Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. Fuse Science's technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For more information or to schedule an interview:

Fuse Science, Inc.
Investor Relations
Direct: (305) 503-3873, Ext. 2
Email: ir@fusescience.com

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science, Inc.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES